The Food and Drug Administration (FDA) is reviewing an ER formulation of alfuzosin hydrochloride 10 mg for once-daily administration for treatment of symptomatic BPH. The IR and twice-daily ER ...

Use of alfuzosin 10 mg once daily increases the likelihood of a successful trial without catheter (TWOC) after acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH), according ...

Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.

The SAMBA trial was an open, noncomparative study conducted in four urology centers in Korea from June 2006 to October 2007. The enrolled patients were followed at baseline and at 4, 12 and 24 weeks ...

Patients who receive alfuzosin as treatment for benign prostatic hyperplasia (BPH) experience improvements in sexual function as well lower urinary tract symptoms (LUTS), a South Korean study suggests ...

The chemistry, pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of alfuzosin hydrochloride in the treatment of benign prostatic hyperplasia (BPH) are discussed. Alfuzosin is a ...